Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research 4: Molecular Markers in Diagnosis and Prognosis 1: Gastrointestinal Malignancies (Colorectal, Gastric, Pancreatic, and Hepatocellular)

Combined targeted inhibition of EGFR tyrosine kinase activity and MEK-1 in human colon cancer cells

Owen Lockerbie
Owen Lockerbie
University of Colorado Cancer Center, Aurora, CO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2005
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 46, 2005

Abstract

1258

Background Both high expression of the EGFR and abnormal activation of downstream signaling, including the Ras/Raf MAP kinase cascade, have been demonstrated in uncontrolled cell proliferation in colorectal cancer (CRC) and other human tumors. For these reasons, the targeted blockade of the EGFR-driven autocrine pathway by small-molecule inhibitors has been proposed as a means of preventing human tumor growth. In this study, using human CRC cell lines, we assessed the in vitro antitumor activities of the combination of ZD6474, an orally active agent that selectively inhibits VEGFR/EGFR tyrosine kinase activity, and UO126, a selective inhibitor of the MEK-1 component of the MAPK pathway. Materials and Methods The antiproliferative effects of 48- and 72-h exposure to ZD6474 and UO126 (as single and combined agents) against human HCT 116 (p53 wt; ras mu) and HT-29 (p53 mu; ras wt) CRC cell lines were determined in separate experiments using a standard MTT assay. Combination effects were analyzed by determining combination index (CI) values using isobolographic methods. Cell-cycle distribution and apoptosis were both quantitated by flow cytometry. Target proteins and phosphorylation of downstream effectors of EGFR were assessed by both Western blot and flow cytometric intracellular staining techniques. Results In both HT29 and HCT116 cells, MTT studies showed that combined drug exposure (0.5μM UO126 and 5μM ZD6474) for either 48 or 72 h resulted in potent synergy (CI values <0.1) for inhibiting proliferation. HT29 cells were notably more sensitive to the combined drug effects on proliferation than HCT116 cells. Cell apoptosis was increased by approximately 3-fold and 1.5-fold by UO126 and ZD6474, respectively, after 72-h exposure, and the increase was more than additive (>6-fold) with combined drug exposure. Combination drug treatment for 72 h also resulted in a marked decrease in expression of the antiapoptotic protein, Bcl-xL. Following 72-h exposure to combination drug treatment, at concentrations that inhibited proliferation and increased apoptosis, there was an increase (∼20%) in the number of HT29 cells in G1, with no obvious effects observed in HCT116 cells. Conclusions These in vitro data indicate that combined targeting of the EGFR and MEK-1 with ZD6474 and UO126, respectively, results in a synergistic inhibition of cell proliferation and induction of apoptosis in human CRC cells. The synergy most likely results from the complementary mechanisms of action of these drugs. In vivo studies in mice are ongoing to investigate combined targeting with these inhibitors in xenograft models of CRC.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 65 (9 Supplement)
May 2005
Volume 65, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Combined targeted inhibition of EGFR tyrosine kinase activity and MEK-1 in human colon cancer cells
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Combined targeted inhibition of EGFR tyrosine kinase activity and MEK-1 in human colon cancer cells
Owen Lockerbie
Cancer Res May 1 2005 (65) (9 Supplement) 292-293;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Combined targeted inhibition of EGFR tyrosine kinase activity and MEK-1 in human colon cancer cells
Owen Lockerbie
Cancer Res May 1 2005 (65) (9 Supplement) 292-293;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Analysis of phospho-signal transducers and activators of transcription 3 (Stat3) (Tyr705) in Japanese gastric cancer shows nuclear localization is associated with a better prognosis
  • Immunohistochemical evaluation and prognostic significance of human kallikreins 6 and 10 in colorectal cancer
  • Quantitative analysis of murine double minute 2(MDM-2)and alternative reading frame(ARF)gene expression in human colorectal carcinoma
Show more Clinical Research 4: Molecular Markers in Diagnosis and Prognosis 1: Gastrointestinal Malignancies (Colorectal, Gastric, Pancreatic, and Hepatocellular)
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement